Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PTCT PTC Therapeutics
41.120
-0.940-2.23%
Post Mkt Price
41.1200.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
56.50% 217.13M 41.87% 165.53M 26.11% 148.74M 41.45% 538.59M
Operating revenue
56.50% 217.13M 41.87% 165.53M 26.11% 148.74M 41.45% 538.59M
Cost of revenue
114.27% 14.01M 31.00% 9.64M 11.32% 10.14M 70.67% 32.33M
Gross profit
53.64% 203.12M 42.60% 155.89M 27.35% 138.6M 39.92% 506.27M
Operating expense
28.96% 276.6M 27.20% 263.45M 14.47% 236.82M 15.99% 881.21M
Selling and administrative expenses
15.69% 80.12M 15.99% 79.89M 19.93% 73.27M 16.56% 285.77M
Research and development costs
26.46% 165.46M 25.33% 157.26M 4.14% 140.08M 13.20% 540.68M
Depreciation amortization depletion
115.69% 31.02M 106.21% 26.29M 108.13% 23.47M 48.41% 54.75M
-Depreciation and amortization
115.69% 31.02M 106.21% 26.29M 108.13% 23.47M 48.41% 54.75M
Operating profit
10.68% -73.49M -9.99% -107.56M -0.18% -98.22M 5.76% -374.94M
Net non-operating interest income expense
4.23% -20.88M 2.58% -21.98M -22.73% -23.51M -52.65% -86.02M
Non-operating interest expense
-4.23% 20.88M -2.58% 21.98M 22.73% 23.51M 52.65% 86.02M
Other net income (expense)
-11.02% -32.84M -875.59% -19.16M 98.59% -155K -211.85% -57.38M
Special income (charges)
149.07% 5.3M 2,271.43% 15.2M 11,800.00% 11.7M 101.48% 500K
-Less:Restructuring and merger&acquisition
-149.07% -5.3M -2,271.43% -15.2M -11,800.00% -11.7M -101.48% -500K
Other non- operating income (expenses)
-103.07% -38.14M -1,183.82% -34.36M -8.92% -11.86M -167.94% -57.88M
Income before tax
4.83% -127.21M -26.14% -148.7M 4.91% -121.89M -28.64% -518.34M
Income tax
-49,602.78% -17.89M 595.08% 3.39M 972.06% 4.84M -84.21% 5.56M
Net income
18.19% -109.32M -28.48% -152.09M 1.49% -126.73M -19.57% -523.9M
Net income continuous Operations
18.19% -109.32M -28.48% -152.09M 1.49% -126.73M -19.57% -523.9M
Minority interest income
Net income attributable to the parent company
18.19% -109.32M -28.48% -152.09M 1.49% -126.73M -19.57% -523.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
18.19% -109.32M -28.48% -152.09M 1.49% -126.73M -19.57% -523.9M
Basic earnings per share
19.05% -1.53 -26.79% -2.13 2.73% -1.78 -11.90% -7.43
Diluted earnings per share
19.05% -1.53 -26.79% -2.13 2.73% -1.78 -11.90% -7.43
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
CEO: Dr. Stuart W. Peltz, PhD
Market: NASDAQ
Listing Date: 06/20/2013
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist